Trial Profile
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 28 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 27 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.